<DOC>
	<DOCNO>NCT00208715</DOCNO>
	<brief_summary>The main purpose study determine Provigil® ( modafinil ) dose 200 mg daily safe effective treating symptom sleepiness fatigue associate Major Depressive Disorder add SSRI .</brief_summary>
	<brief_title>Provigil Conjunction With SSRIs Treatment Mild Moderate Depression With Attendant Symptoms Sleepiness Fatigue .</brief_title>
	<detailed_description>Approximately 100 male female outpatient , age 18 65 , enrol four site United States . This study consist two part . The first part consist 6 week open label treatment select SSRI &amp; double blind treatment Provigil placebo ( inactive medication ) . After six week double blind treatment phase patient enter four week open label treatment phase Provigil . The dose Provigil exceed 400 mg less 100 mg per day . They continue take prescribe SSRI .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Major Depressive Disorder MADRS score ≥ 15 screen &amp; baseline . Significant fatigue evidence FSS ≥4 screen &amp; baseline . Excessive sleepiness evidence ESS ≥ 10 screen &amp; baseline . Treatment refractory depression Serious unstable medical condition . Pregnancy Primary diagnosis another Axis I II disorder Alcohol substance abuse dependence within past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Depression</keyword>
</DOC>